Healthy Skepticism Announcements
DIDA: Premarin, Rockpinte, Paxil, Lexapro
Kim Klausner has announced today that 15 new documents have been added to the Drug Industry Document Archive (DIDA). You can find them by typing in “ddu:20091112†without the quotation marks in the query box at http://dida.library.ucsf.edu. (A few of the documents in this batch replace damaged ones so are not strictly “new.â€)
The documents include:
Depositions from Karen Mittleman, the DesignWrite staffer who worked on Wyeth’s publication plan for Premarin (conjugated estrogens) products. She responds to questions about how academic authors, her medical communications company and the drug manufacturer implemented its plan. (Parts of these documents appear redacted because the version we received had highlighting which doesn’t OCR well.)
A letter from Thomas Sullivan, President of Rockpointe, a medical communications firm, spells out the terms under which his company does business with numerous drug company clients and clarifies his relationship with ACRE, the Association of Clinical Researchers and Educators. He also provides a list of payments from drug and medical device companies for Rockpointe services from 2006 to June 2009.
The 1999 Tactical Plan for Paxil (paroxetine) which includes participation in ISAAC (Initiative for Social Anxiety Assessment and Care), a disease-based registry of potential patients/customers, for which physicians will be paid $100 for each person recruited.
The 2004 Lexapro (escitalopram) Marketing Plan which includes this gem:
“Bylined articles will allow us to fold Lexapro messages into articles on depression, anxiety and comorbidity developed by (or ghostwritten for) thought leaders” (page 23).
Page views since 15 March 2010: 3074
Comments
Our members can see and make comments on this page.
